Julia Kitz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julia Kitz has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Gaumann
Institute of Pathology Kaufbeuren-Ravensburg, Kaufbeuren, Germany
1 shared publication - Antje Krohn
Department of Pathology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, D-20246 Hamburg, Germany
1 shared publication - Eva Wardelmann
Gerhard-Domagk-Institute of Pathology, University Hospital Münster, 48149 Münster, Germany
1 shared publication - Florian Haller
Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
1 shared publication - Gunhild Mechtersheimer
Institute of Pathology, University of Heidelberg, 69120 Heidelberg, Germany
1 shared publication - Hans Ulrich Schildhaus
Universitätsklinikum Bonn
1 shared publication
Latest Publications
- Open Access
- 4 July 2010
- Published by Springer Nature in BMC Medical Genetics
- Vol. 11 (1) , 106
Pitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors
Mutation analysis of KIT and PDGFRA genes in gastrointestinal stromal tumors is gaining increasing importance for prognosis of GISTs and for prediction of treatment response. Several groups have identified specific mutational subtypes in KIT exon 11 associated with an increased risk of metastatic disease whereas GISTs with PDGFRA mutations often behave less aggressive. Furthermore, in advanced GIST disease with proven KIT exon 9 mutation the doubled daily dose of 800 mg imatinib increases the progression free survival and is now recommended both in the European and the American Guidelines. In Germany, there are still no general rules how to perform mutational analysis.
- 4 July 2010
- Published by Springer Nature in BMC Medical Genetics
- Vol. 11 (1) , 106
Open AccessPitfalls in mutational testing and reporting of common KIT and PDGFRA mutations in gastrointestinal stromal tumors
Mutation analysis of KIT and PDGFRA genes in gastrointestinal stromal tumors is gaining increasing importance for prognosis of GISTs and for prediction of treatment response. Several groups have identified specific mutational subtypes in KIT exon 11 associated with an increased risk of metastatic disease whereas GISTs with PDGFRA mutations often behave less aggressive. Furthermore, in advanced GIST disease with proven KIT exon 9 mutation the doubled daily dose of 800 mg imatinib increases the progression free survival and is now recommended both in the European and the American Guidelines. In Germany, there are still no general rules how to perform mutational analysis.